Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion

Launched by KING'S COLLEGE HOSPITAL NHS TRUST · Nov 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new device called the IKORUS, which is designed to help manage blood flow in critically ill patients. The goal is to see if the device is safe and effective for use in patients who are in the Intensive Care Unit (ICU). Researchers want to understand how well the device can help keep blood circulation stable in these patients.

To be eligible for this trial, patients must be admitted to the ICU within the last 24 hours and expect to stay there for at least five days. They should also be receiving a specific medication called noradrenaline to help support their blood pressure. However, patients who are receiving care solely for comfort (palliative treatment), have had complications with catheter placement, or cannot safely receive certain treatments will not be included. Participants in the trial will have the opportunity to help advance medical knowledge while receiving close monitoring and care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Within 24 h of ICU admission
• • Predicted length of ICU stay at least 5 days
• • Receiving \>0.1 mcg/kg/min of noradrenaline at time of study enrolment
• Exclusion Criteria:
• • Palliative treatment intent
• • Contra indication to urethral catheterisation or complication during previous urethral catheter insertion
• • Contraindication to fluid or vasopressor challenges in the opinion of the attending clinician